

1 **Title Page**

2

3 **Title:** Characterizing HIV status documentation among cancer patients at regional cancer centers in Malawi,  
4 Zimbabwe, and South Africa

5

6 **Authors:** Michalina A Montaño<sup>1,2,3</sup>, Takudzwa Mtisi<sup>4</sup>, Ntokozo Ndlovu<sup>4</sup>, Margaret Borok<sup>4</sup>, Agatha Bula<sup>5</sup>,  
7 Maureen Joffe<sup>6</sup>, Rachel Bender Ignacio<sup>2,3\*</sup>, Maganizo B Chagomerana<sup>5,7\*</sup>

8

9 <sup>1</sup>University of Washington, Department of Global Health

10 <sup>2</sup>University of Washington, Department of Medicine, Division of Allergy and Infectious Diseases

11 <sup>3</sup>Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division

12 <sup>4</sup>University of Zimbabwe, Faculty of Medicine and Health Sciences

13 <sup>5</sup>UNC Project Malawi

14 <sup>6</sup>University of the Witwatersrand, Faculty of Health Sciences, Strengthening Oncology Services Research Unit

15 <sup>7</sup>University of North Carolina at Chapel Hill, Department of Medicine

16

17 \*Contributed equally

18

19 **Corresponding author:**

20 Michalina A Montaño

21 micham@uw.edu

22

## 23 **Abstract**

## 24 **Introduction**

25 In East and Southern Africa, people with HIV (PWH) experience worse cancer-related outcomes and are at  
26 higher risk of developing certain cancers. Siloed care delivery pathways pose a substantial barrier to co-  
27 management of HIV and cancer care delivery.

## 28 **Methods**

29 We conducted cross-sectional studies of adult cancer patients at public radiotherapy and oncology units in  
30 Malawi (Kamuzu Central Hospital), Zimbabwe (Parirenyatwa Group of Hospitals), and South Africa (Charlotte  
31 Maxeke Hospital) between 2018-2019. We abstracted cancer- and HIV-related data from new cancer patient  
32 records and used Poisson regression with robust variance to identify patient characteristics associated with  
33 HIV documentation.

## 34 **Results**

35 We included 1,648 records from Malawi (median age 46 years), 1,044 records from South Africa (median age  
36 55 years), and 1,135 records from Zimbabwe (median age 52 years). Records from all three sites were  
37 predominately from female patients; the most common cancers were cervical (Malawi [29%] and Zimbabwe  
38 [43%]) and breast (South Africa [87%]). HIV status was documented in 22% of cancer records from Malawi,  
39 92% from South Africa, and 86% from Zimbabwe. Patients with infection-related cancers were more likely to  
40 have HIV status documented in Malawi (adjusted prevalence ratio [aPR]: 1.92, 95% confidence interval [CI]:  
41 1.56-2.38) and Zimbabwe (aPR: 1.16, 95%CI: 1.10-1.22). Patients aged  $\geq 60$  years were less likely to have HIV  
42 status documented (Malawi: aPR: 0.66, 95% CI: 0.50-0.87; Zimbabwe: aPR: 0.76, 95%CI: 0.72-0.81) than  
43 patients under age 40 years. Patient age and cancer type were not associated with HIV status documentation  
44 in South Africa.

## 45 **Conclusion**

46 Different cancer centers have different gaps in HIV status documentation and will require tailored strategies to  
47 improve processes for ascertaining and recording HIV-related information in cancer records. Further research  
48 by our consortium to identify opportunities for integrating HIV and cancer care delivery is underway.

49

50

51 **Keywords:**

52 HIV, oncology, epidemiology, Malawi, South Africa, Zimbabwe

53

## 54 INTRODUCTION

55 In East and Southern Africa, cancer disproportionately impacts people with HIV (PWH). PWH are at  
56 higher risk of developing certain cancers (1, 2), and experience worse cancer-related outcomes, including  
57 higher risk of treatment complications, more rapid progression, and higher cancer-specific mortality (2-7).  
58 Since 2016, the World Health Organization has recommended that all PWH begin lifelong antiretroviral therapy  
59 (ART) as soon as possible after diagnosis. Immediate ART reduces overall morbidity and mortality from HIV-  
60 associated malignancies and other diseases (8-10). Cancer treatment guidelines for PWH recommend co-  
61 management of HIV and cancer care to ensure uninterrupted ART during cancer therapy (11). However, the  
62 guidelines lack specific recommendations beyond ensuring standard of care HIV therapy, and there is a lack of  
63 evidence-based guidance for co-management of HIV and cancer care delivery in resource-constrained  
64 settings. Siloed care delivery pathways and limited facilities for cancer treatment make co-management of HIV  
65 and cancer care delivery difficult (12), with evidence that engagement and barriers to HIV care impact receipt  
66 of timely cancer care in this setting (13).

67 Ascertaining the HIV status of patients being treated for cancer is a critical step in successful cancer  
68 treatment. Stable and continuous access to ART throughout cancer treatment is associated with better  
69 tolerance of cancer therapy, higher response rates, and improved survival (14, 15). Conversely, PWH with  
70 moderate to severe immunosuppression have an increased risk of morbidity and mortality from radiation and  
71 cytotoxic chemotherapy, likely due to a compounding effect of these therapies on existing HIV-related  
72 immunosuppression (16, 17). ART decreases immune exhaustion and restores cell-mediated immunity among  
73 PWH (18, 19), which may improve cancer treatment outcomes by preventing further immunosuppression.  
74 Ascertaining HIV and antiretroviral treatment status for all patients being treated for cancer is necessary to  
75 avoid poor cancer-related outcomes, as well as to decrease risk of infections and all-cause mortality among  
76 people who may be unaware of their HIV status or not receiving ART (10).

77 Integration of HIV and cancer care delivery could improve cancer outcomes for people with comorbid  
78 cancer and HIV. Critical first steps to integrating HIV and cancer care delivery in East and Southern Africa  
79 include understanding both the burden of HIV at cancer treatment centers, and the scope of HIV-related  
80 documentation in cancer center records. Identifying gaps in HIV status ascertainment is the most basic  
81 component of cancer care teams being able to optimize clinical decision-making for PWH who are being

82 treated for cancer. HIV testing and treatment cascades continue to improve in the region, and integrating HIV  
83 and cancer-related service delivery will require that these improvements be reflected in cancer-related records.  
84 We formed a new consortium across cancer referral centers in East and Southern Africa to study and  
85 implement improved HIV care for cancer patients. In this first evaluation, we measured HIV status  
86 documentation in medical records at national referral cancer treatment centers in Malawi, South Africa, and  
87 Zimbabwe, and assessed demographic and clinical characteristics associated with HIV status documentation  
88 in cancer records.

## 90 **METHODS**

### 91 *Study design, setting, and population*

92 We conducted cross-sectional studies of adult cancer patients at three cancer treatment centers  
93 participating in our consortium from Malawi (Kamuzu Central Hospital (KCH)), South Africa (Charlotte Maxeke  
94 Johannesburg Academic Hospital (CMJAH)), and Zimbabwe (Parirenyatwa Group of Hospitals (PGH)). KCH is  
95 one of two national teaching hospitals in Malawi and provides oncology services to half of the country's  
96 population. Radiotherapy services were not available in Malawi, and patients requiring radiation to treat their  
97 cancer during the study period were referred to institutions outside the country (20). CMJAH is a quaternary-  
98 care teaching hospital located in Johannesburg, affiliated with the University of the Witwatersrand, and  
99 provides complete diagnostic, surgical, radiation and medical oncology services for Johannesburg and national  
100 referrals. PGH is a tertiary-care teaching hospital in Harare affiliated with the University of Zimbabwe and is  
101 one of two public cancer treatment facilities in the country; PGH provides radiation, medical and surgical  
102 oncology services to two thirds of Zimbabwe's population (21). We limited analysis to all new patients  
103 registered during 2018 and 2019, and excluded patients who were under age 18 years, those with a known  
104 recurrent cancer diagnosis, and those with benign diagnoses.

### 106 *Data sources and measures*

107 At KCH, we obtained data from the KCH Cancer Registry, a hospital-based registry which collects data  
108 on demographic and clinical characteristics for all persons with cancer presenting to KCH during 2018-2019,  
109 including cancer diagnosis and HIV status (22). KCH Cancer Registry data are abstracted directly from hospital

110 records. At CMJAH, we abstracted data from patient medical records from the Department of Medical  
111 Oncology and research records from a large breast cancer cohort. At PGH, we abstracted data from patient  
112 medical records from the Radiotherapy and Oncology Centre (ROC). PGH has a Kaposi Sarcoma Clinic  
113 separate from the ROC, and KS patients were therefore not included among the reviewed records unless they  
114 were receiving treatment at the ROC.

115 We collected data on age, sex, district or province of residence, cancer diagnosis, and HIV status  
116 (positive/negative/not documented). Based on residence data, we categorized participants as either residing  
117 outside or in the same province/district as the cancer center at which they were receiving cancer treatment.  
118 Due to the strong association between oncogenic viral infections and HIV, we categorized cancer diagnoses as  
119 either infection-related or not infection-related. Cancers that are most likely or universally resultant from  
120 oncogenic viral infection (Epstein-Barr virus, Hepatitis B and C viruses, human papillomavirus (HPV), Kaposi  
121 sarcoma-associated herpesvirus) were categorized as infection-related cancers: Hodgkin and non-Hodgkin  
122 lymphomas, liver cancers, anal, cervical, penile, and vulvovaginal cancers, and Kaposi sarcoma (23). We did  
123 not consider cancers of mixed pathogenesis (e.g., head and neck or gastric, which may or may not be  
124 attributable to HPV and *H. pylori*, respectively), as infection-related, due to inability to confirm histology and  
125 infectious etiology in all cases.

### 126 127 *Statistical analysis*

128 Descriptive statistics for demographic and clinical characteristics of all participants included in the  
129 analysis were summarized separately for each study site. We calculated the proportion of participants with HIV  
130 status documented in their medical records, and the HIV prevalence among those with documented HIV  
131 status. We used generalized linear models with Poisson distribution and robust variance to identify participant  
132 characteristics associated with documented HIV status. We selected covariates *a priori* based on  
133 characteristics previously documented to be associated with either HIV testing or barriers to HIV care  
134 engagement in these regions (24-27). The covariates of interest included age, gender, residence proximity to  
135 cancer treatment center, and infection-related cancer diagnosis. We developed separate models for each  
136 study site to understand the context of HIV status documentation separately for each cancer center and assist

with developing site-specific solutions to improve status documentation. Two-sided statistical tests were performed at an alpha level of 0.05. We used Stata version 17.0 (College Station, Texas) for all analyses.

This study was approved by the University of Washington Institutional Review Board, University of North Carolina Institutional Review Board, Malawi National Health Sciences Research Committee, University of the Witwatersrand Human Research Ethics Committee (Medical), and the Joint Research Ethics Committee for the University of Zimbabwe Faculty of Medicine and Health Sciences and Parirenyatwa Group of Hospitals. Patients were not involved in the design or conduct of this research.

## RESULTS

### *Malawi*

We included 1,648 records from KCH, Malawi. Participants had a median age of 46 years and were predominantly female (Table 1). Most participants (72.3%) reported residing in Lilongwe district, where KCH is located. Infection-related cancers were common and accounted for over half of all cancer diagnoses. HIV status was documented in 22% of available cancer records. Among patients with documented HIV status, 47% were HIV-positive. Data on ART status was not available in cancer records from Malawi. The most common cancers were cervical, breast, Kaposi sarcoma, and non-Hodgkin lymphoma, among which the proportion of records with no HIV status documented was 80.3%, 84.9%, 75.3%, and 46.9%, respectively (Table 2; Figure 1). We observed differences in HIV status documentation by age, gender, residence proximity to KCH, and infection-related cancer status (Table 3). Patients aged 60 years or older were less likely to have their HIV status documented (adjusted prevalence ratio [aPR]: 0.66, 95% confidence interval [CI]: 0.50-0.87). Male patients were more likely to have HIV status documented compared to female patients (aPR: 1.45, 95% CI: 1.21-1.74). Similarly, patients residing outside Lilongwe district were more likely to have HIV status documented compared to patients residing within Lilongwe district (aPR: 1.68, 95% CI: 1.41-2.01). Patients with infection-related cancers were also more likely to have HIV status documented than patients with non-infection-related cancers (aPR: 1.92, 95%CI: 1.56-2.38).

### *South Africa*

165 We included 1,044 records from CMJAH, South Africa. Over 90% of participants from this site were  
166 female, and the median age was 55 years. Almost all participants (97.0%) reported residing in Gauteng  
167 Province, where CMJAH is located. Infection-related cancers were not common among available data from  
168 CMJAH; data were obtained primarily from patients with breast cancer (86.9% of available records at the  
169 sampled clinic). HIV status was documented among 91.7% of available cancer records, and HIV prevalence  
170 was 24.2% among those with documented HIV status. Among patients with documented HIV, 96.9% were on  
171 ART at the time they registered as patients at CMJAH. Among patients with breast cancer, 7.3% had no HIV  
172 status documented in their cancer record. Patient age, gender, residence, and cancer type were not  
173 associated with HIV status documentation in South Africa.

### 174 *Zimbabwe*

175 We included 1,135 records from PGH, Zimbabwe. Participants had a median age of 52 years, and  
176 three quarters were female. Most participants (65.4%) resided outside Harare Province, where PGH is located.  
177 Infection-related cancers were common, accounting for 49.8% of cancer diagnoses. HIV status was  
178 documented in 86% of available cancer records. Among patients with documented HIV status, HIV prevalence  
179 was 37%. Among patients with documented HIV, 95.6% were on ART at the time they registered at PGH. The  
180 most common cancers were cervical, head and neck, and breast, among which 3.5%, 14.7%, and 16.8%,  
181 respectively, had no HIV status documented in cancer records (Table 2; Figure 1). We observed differences in  
182 HIV status documentation by age and infection-related cancer status. Patients aged 60 years or older were  
183 less likely to have their HIV status documented compared to patients under age 40 years (aPR 0.76, 95%CI:  
184 0.72-0.81). Patients with infection-related cancers were more likely than those with non-infection-related  
185 cancers to have their HIV status documented (aPR: 1.16, 95%CI:1.10-1.22) (Table 4). Gender and residence  
186 proximity to cancer center were not significant predictors of HIV status documentation in multivariable models.  
187

## 188 **DISCUSSION**

189 The objectives of this project were to document the burden of HIV among patients with cancer,  
190 measure HIV status documentation in cancer records, and identify characteristics associated with  
191 undocumented HIV status. The goal of these activities was to provide context-specific recommendations for  
192



193 improvement of HIV status documentation, and guide future strategies to integrate components of HIV care  
194 delivery into cancer care for PWH. Amongst the three sites studied in this new consortium focused on  
195 implementing coordinated HIV and cancer care, we found variable needs in achieving universal HIV  
196 documentation at each center. While Zimbabwe and South Africa had high rates of HIV documentation with  
197 near complete documentation of ART receipt for those with documented HIV, a minority of cancer patients in  
198 Malawi had HIV status available in their records. Among cancer patients with documented status, the  
199 prevalence of HIV was much higher than in the general population, even considering the older age distribution  
200 of cancer patients compared to the general population in each country.

### 202 *Malawi*

203 In Malawi, HIV status was documented in 22% of cancer records. In this study, HIV prevalence among  
204 patients with documented HIV status was almost five times the general population HIV prevalence, and over  
205 three times the prevalence for adults over age 50 years (28). Over three quarters of cancer records did not  
206 have HIV status documented. Malawi has made considerable progress toward meeting the first and second  
207 Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets; 98% of women and 89% of men  
208 over age 15 years and living with HIV in Malawi are aware of their HIV status, and 97% of PWH aware of their  
209 status are on ART (29). The high proportion of patients with undocumented HIV status that we observed may  
210 be due to failure to document HIV-related information in cancer records rather than lack of HIV testing in this  
211 population. While HIV testing rates are higher among women in Malawi (26, 28), men were more likely than  
212 women to have their HIV status documented in cancer records, which may further support that those tested in  
213 outside settings were less likely to have those results reported than those tested for indications associated with  
214 their cancer diagnosis.

215 The high HIV prevalence we observed among patients with their HIV status documented may be due to  
216 indication bias. Patients with infection-related cancers (signs and symptoms possibly indicative of HIV) may be  
217 more likely to be referred for HIV testing during cancer care delivery and would therefore be more likely to have  
218 their HIV status documented than patients with other cancers. Patients with infection-related cancers were  
219 more likely to test positive for HIV than patients with non-infection-related cancers. The HIV prevalence among

220 patients with their HIV status documented may therefore not accurately represent the HIV prevalence among  
221 the overall population of patients with cancer.

222 Knowing patients' ART status and regimen likely also improves cancer care decision-making, but  
223 clinical care teams are at a disadvantage if this information is not recorded and available to them. Malawi's  
224 progress meeting the 95-95-95 targets suggests that changes to the way HIV-related information is  
225 ascertained by cancer care teams and documented in cancer records may result in substantial improvements  
226 in HIV care coordination among cancer patients, even while most cancer patients are likely already aware of  
227 their status. Strategies to improve HIV testing can then be targeted to the small proportion of patients with  
228 cancer whose HIV status is truly unknown rather than those whose HIV status is known but not documented.

### 229 *South Africa*

230  
231 In South Africa, HIV status was documented in 92% of cancer records. We did not find characteristics  
232 associated with HIV status documentation among this patient population. A high proportion of PWH had their  
233 ART status recorded, and were on ART. However, the majority of available data were from patients with breast  
234 cancer due to the population at the specific clinic sampled, and the results may not generalize to other  
235 cancers. Specifically, there has been concerted effort at this institution to create algorithms for breast cancer  
236 providers to ensure HIV testing and care are secured prior to cancer treatment (30, 31). This may have  
237 impacted our overall ability to measure associations between patient characteristics and HIV status  
238 documentation, and these associations should be explored among patients with other types of cancer in this  
239 and similar institutions. Recent data from UNAIDS shows 94% of PWH in South Africa know their status, which  
240 is reflected in the high proportion of cancer records with HIV status documented at CMJAH (29). Further along  
241 the HIV care cascade, however, only 78% of South African women and 68% of men with HIV over age 15  
242 years are on ART. Among records included in our analysis, we found that 97% of PWH being treated for  
243 cancer at CMJAH were on ART, a higher proportion than the general population of PWH. This may be due in  
244 part to specific protocols for cancer treatment at CMJAH, especially for people with breast cancer, and possible  
245 higher engagement in clinical care among people with cancer.

### 246 247 *Zimbabwe*

248 In Zimbabwe, HIV status was documented in 86% of cancer records. People over age 60 years and  
249 those with non-infection related cancers were less likely to have their HIV status documented, and increasing  
250 HIV status ascertainment for these groups will be necessary to meet the goal of universal HIV status  
251 ascertainment for cancer patients. Among patients with documented HIV status, the HIV prevalence was 37%,  
252 which is triple the general population prevalence, and double the HIV prevalence for adults over age 50 years  
253 (32). Among patients with a documented positive HIV status, the vast majority had their ART status  
254 documented, and were on ART at the time they entered care at PGH. This suggests that almost all patients  
255 with cancer at PGH who know their HIV status are already established in HIV care when they enter cancer  
256 care. Demographic data show that two thirds of PGH cancer patients reside in a different province from where  
257 the cancer center is located. Since most PWH access HIV care near where they live, a substantial proportion  
258 of PWH accessing cancer therapy at PGH may experience disruptions to HIV care access due to traveling to  
259 receive cancer therapy, as previously demonstrated in Uganda by members of our consortium (33). Any  
260 integration of HIV and cancer service delivery at PGH should include strategies to ensure these patients can  
261 reliably access their ART during cancer treatment. Finally, like Malawi, Zimbabwe has met the UNAIDS 90-90-  
262 90 goals and is progressing toward the new 95-95-95 targets (29). Among PWH, 98% of women and 95% of  
263 men aged 15 years or older know their status, and 96% of those who know their status are on ART. If HIV  
264 testing and ART use among Zimbabweans with cancer are similar to the general population, this suggests that  
265 improvements to HIV status documentation, supplemented by targeted HIV testing for people with unknown  
266 status, is likely to bridge the gap to achieving universal HIV status ascertainment for people with cancer being  
267 treated at PGH, especially for those with malignancies not typically considered HIV-associated.

268  
269 Data on the burden of HIV and HIV status documentation among patients with cancer from other  
270 countries in East and Southern Africa are sparse. A cross-sectional study conducted in Uganda in 2015  
271 reported that 29% of patients with cancer at the Uganda Cancer Institute had no recorded HIV status (34).  
272 Among patients with HIV status documented, 32% had HIV, more than four-fold higher than the general  
273 population prevalence (7%) at the time. Another study, conducted between 2014 and 2016 in Malawi, was able  
274 to ascertain the HIV status of 34% of registered cancer patients at KCH, of whom 58% had HIV (22). This  
275 proportion is substantially higher than the general population HIV prevalence, but like our findings from KCH

276 reported above, may not accurately reflect the prevalence of HIV among all cancer patients due to the high  
277 proportion of missing data. Importantly, the timelines of these two studies coincided with early scale up of  
278 strategies to meet the newly established 90-90-90 goals but largely preceded removal of CD4 thresholds for  
279 ART initiation by the WHO (35). Since then, the proportion of people who know their HIV status has improved  
280 across East and Southern Africa (29). It seems unlikely that people with cancer are much less likely to receive  
281 HIV testing and know their status than the general population, and gaps in HIV status ascertainment for  
282 patients with cancer may be partly due to siloing of information and care rather than lack of testing; stigma  
283 around both HIV and cancer and use of hand-carried HIV records in many locations may contribute to lack of  
284 HIV documentation(18).

285 Our findings suggest that different cancer centers will require tailored strategies to address gaps in HIV  
286 and HIV-treatment status documentation for patients with cancer as a first step in providing coordinated HIV  
287 and cancer care. The proportions of cancer patients without documented HIV status reported above include  
288 both people with cancer who are unaware of their HIV status, and those who know their status, but whose  
289 status may not be available to their cancer care team. The high proportion of PWH in Malawi, South Africa, and  
290 Zimbabwe who know their status suggests that under-ascertainment of HIV status for patients with cancer may  
291 be primarily a result of siloed care delivery systems in these locations. Improving cancer care for PWH will  
292 require that cancer providers and clinical care teams also know the HIV and ART status of their patients.  
293 Improving ascertainment will likely require a combination of approaches that are site-specific. Changes to the  
294 process for ascertaining and recording HIV status and other HIV-related information in cancer-related medical  
295 records may result in marked improvement in HIV status documentation overall, with HIV testing to supplement  
296 these medical record system changes focused on patients with unknown HIV status. Further research to  
297 identify and apply context-specific opportunities for integrating HIV and cancer care delivery may be necessary  
298 to improve outcomes for patients with comorbid HIV and cancer in East and Southern African settings. Work by  
299 our consortium is ongoing at these three sites plus the Uganda Cancer Institute, to identify opportunities to  
300 integrate HIV care into cancer care, starting with developing site-specific process maps and institutional  
301 barriers and facilitators to providing coordinated HIV treatment initiation and continuity for those receiving  
302 cancer care.

304 **Abbreviations**

305 aPR: adjusted prevalence ratio

306 ART: antiretroviral therapy

307 CI: confidence interval

308 CMJAH: Charlotte Maxeke Johannesburg Academic Hospital

309 HIV: Human Immunodeficiency Virus

310 HPV: Human papillomavirus

311 KCH: Kamuzu Central Hospital

312 KS: Kaposi Sarcoma

313 PGH: Parirenyatwa Group of Hospitals

314 PWH: People with HIV

315 ROC: Radiation and Oncology Centre

316

317 **DECLARATIONS**

318

319 **Ethics Approval**

320 All procedures performed in this study involving human participants were in accordance with the ethical  
321 standards of the institutional and/or national research committees, and with the 1964 Helsinki declaration and  
322 its later amendments or comparable ethical standards. The study received ethical approval from the University  
323 of Washington Institutional Review Board, University of North Carolina Institutional Review Board, Malawi  
324 National Health Sciences Research Committee, University of the Witwatersrand Human Research Ethics  
325 Committee (Medical), and the Joint Research Ethics Committee for the University of Zimbabwe Faculty of  
326 Medicine and Health Sciences and Parirenyatwa Group of Hospitals.

327

328 **Consent for Publication**

329 Not applicable

330

331 **Availability of Data and Materials**

332 The data that support the findings of this study are not publicly available due to privacy or ethical restrictions.  
333 Data are available from the authors upon reasonable request and permission from each participating hospital  
334 and institutional review board.

335

336 **Competing Interests**

337 All authors declare they have no competing interests.

338

339 **Funding**

340 This study was funded by the National Institutes of Health: National Institute of Allergy and Infectious Diseases  
341 (R21 AI155055) and National Cancer Institute (T32 CA080416).

342

343 **Author Contributions**

344 Conception and study design: MB, MBC, MJ, MAM, NN, RBI; data collection: all authors; data analysis: MBC,  
345 MAM, TM; review and interpretation of results: all authors; manuscript preparation: MAM; manuscript revision  
346 and final approval of the submitted manuscript: all authors.

347

### 348 **Acknowledgements**

349 The authors wish to thank the staff at PGH, University of Zimbabwe, CMJAH, Wits Health Consortium, KCH,  
350 and UNC Project Malawi who assisted with data collection for this study.

351

352

## REFERENCES

1. Yarchoan R, Uldrick TS. HIV-Associated Cancers and Related Diseases. *The New England journal of medicine*. 2018;378(11):1029-41.
2. Chinula L, Moses A, Gopal S. HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities. *Curr Opin HIV AIDS*. 2017;12(1):89-95.
3. Reddy P, Ebrahim S, Singh B, Ramklass S, Buccimazza I. Breast Cancer and HIV: a South African perspective and a critical review of the literature. *South African journal of surgery Suid-Afrikaanse tydskrif vir chirurgie*. 2017;55(1):10-5.
4. Simonds HM, Botha MH, Neugut AI, Van Der Merwe FH, Jacobson JS. Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort. *Gynecologic oncology*. 2018;151(2):215-20.
5. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, et al. HIV Infection and Survival Among Women With Cervical Cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;34(31):3749-57.
6. Ngidi S, Magula N, Sartorius B, Govender P, Madiba TE. Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy. *S Afr Med J*. 2017;107(7):595-601.
7. Camandaroba MPG, de Araujo RLC, Silva VSE, de Mello CAL, Riechelmann RP. Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. *J Gastrointest Oncol*. 2019;10(1):48-60.
8. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what's new.: World Health Organization; 2015.
9. Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. *The New England journal of medicine*. 2015;373(9):808-22.
10. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *The New England journal of medicine*. 2015;373(9):795-807.
11. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2018;16(8):986-1017.
12. Koh WJ, Anderson BO, Carlson RW. NCCN resource-stratified and harmonized guidelines: A paradigm for optimizing global cancer care. *Cancer*. 2020;126 Suppl 10:2416-23.
13. Low DH, Phipps W, Orem J, Casper C, Bender Ignacio RA. Engagement in HIV Care and Access to Cancer Treatment Among Patients With HIV-Associated Malignancies in Uganda. *J Glob Oncol*. 2019;5:1-8.
14. Hessel NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. *Am J Epidemiol*. 2007;165(10):1143-53.
15. Montañó MA, Chagomerana MB, Borok M, Painschab M, Uldrick TS, Bender Ignacio RA. Impact of Antiretroviral Therapy on Cancer Treatment Outcomes among People Living with HIV in Low- and Middle-Income Countries: a Systematic Review. *Curr HIV/AIDS Rep*. 2021;18(2):105-16.
16. Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, et al. Time for oncologists to opt in for routine opt-out HIV testing? *Jama*. 2010;304(3):334-9.
17. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. *Curr Opin Oncol*. 2009;21(5):445-54.
18. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. *AIDS (London, England)*. 2003;17(13):1907-15.
19. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;44(5):749-54.
20. Kamuzu Central Hospital - National Cancer Center [Available from: <https://www.esmo.org/for-patients/esmo-designated-centres-of-integrated-oncology-palliative-care/esmo-accredited-designated-centres/kamuzu-central-hospital-national-cancer-center>].



21. The National Cancer Prevention And Control Strategy For Zimbabwe 2014 - 2018. Zimbabwe Ministry of Health and Child Care; 2014.
22. Horner MJ, Salima A, Chilima C, Mukatipa M, Kumwenda W, Kampani C, et al. Frequent HIV and Young Age Among Individuals With Diverse Cancers at a National Teaching Hospital in Malawi. *J Glob Oncol.* 2018;4:1-11.
23. Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. *Nat Rev Microbiol.* 2018;16(11):684-98.
24. Croome N, Ahluwalia M, Hughes LD, Abas M. Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. *Aids.* 2017;31(7):995-1007.
25. Hakim AJ, Tippett Barr BA, Kinchen S, Musuka G, Manjengwa J, Munyati S, et al. Progress Toward the 90-90-90 HIV Targets in Zimbabwe and Identifying Those Left Behind. *J Acquir Immune Defic Syndr.* 2021;88(3):272-81.
26. Maman D, Ben-Farhat J, Chilima B, Masiku C, Salumu L, Ford N, et al. Factors associated with HIV status awareness and Linkage to Care following home based testing in rural Malawi. *Trop Med Int Health.* 2016;21(11):1442-51.
27. West CA, Chang GC, D WC, Bray R, Kinchen S, Behel S, et al. Unawareness of HIV Infection Among Men Aged 15-59 Years in 13 Sub-Saharan African Countries: Findings From the Population-Based HIV Impact Assessments, 2015-2019. *J Acquir Immune Defic Syndr.* 2021;87(Suppl 1):S97-s106.
28. Malawi Population-based HIV Impact Assessment 2020-2021 (MPHIA 2020-2021): Final Report. Lilongwe: MOH Malawi November 2022.
29. UNAIDS Data 2022. Geneva: Joint United Nations Programme on HIV/AIDS; 2022.
30. Chasimpha S, McCormack V, Cubasch H, Joffe M, Zietsman A, Galukande M, et al. Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study. *The Lancet HIV.* 2022;9(3):e160-e71.
31. Cubasch H, Joffe M, Hanisch R, Schuz J, Neugut AI, Karstaedt A, et al. Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa. *Breast cancer research and treatment.* 2013;140:177-86.
32. Zimbabwe Population-based HIV Impact Assessment 2020 (ZIMPHIA 2020): Final Report. Harare December 2021.
33. Low DH, Phipps W, Orem J, Casper C, Bender Ignacio RA. Engagement in HIV Care and Access to Cancer Treatment Among Patients With HIV-Associated Malignancies in Uganda. *Journal of Global Oncology.* 2019(5):1-8.
34. Bender Ignacio R, Ghrdrshenas M, Low D, Orem J, Casper C, Phipps W. HIV Status and Associated Clinical Characteristics Among Adult Patients With Cancer at the Uganda Cancer Institute. *J Glob Oncol.* 2018;4:1-10.
35. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.

<b>Table 1. Demographic and Clinical Characteristics of Adult Cancer Patients at Regional Cancer Treatment Centres in Malawi, South Africa, and Zimbabwe</b>						
	Malawi N=1648		South Africa N=1044		Zimbabwe N=1135	
Characteristic	n	%	n	%	n	%
<b>Age at Diagnosis</b>						
<40	534	32.4	173	16.6	175	15.4
40-49	429	26.0	255	24.4	288	25.4
50-59	314	19.2	293	28.1	215	18.9
60 or older	368	22.3	323	30.9	457	40.3
<b>Gender</b>						
Female	1040	63.1	964	92.3	829	73.0
Male	605	36.7	80	7.7	306	27.0
<b>Residence Proximity to Hospital</b>						
Resides in same province as hospital	1191	72.3	1013	97.0	393	34.6
Resides outside hospital province	446	27.1	11	1.1	742	65.4
<b>Infection-Related Cancer Status</b>						
Not infection-related	715	43.4	994	95.2	570	50.2
Infection-related	933	56.6	50	4.8	565	49.8
<b>HIV Status Documentation</b>						
Not Documented	1286	78.0	87	8.3	155	13.7
Documented	362	22.0	957	91.7	980	86.3
<b>HIV Status<sup>a</sup></b>						
HIV-Negative	191	52.8	725	75.8	614	62.7
HIV-Positive	171	47.2	232	24.2	366	37.3
<b>ART Status<sup>b</sup></b>						
On ART	--	--	219	96.9	350	95.6
Not on ART	--	--	6	2.7	7	1.9
ART status not documented	--	--	1	0.4	9	2.5

Due to missing values, percentages may not sum to 100%. 3 participants from Malawi missing age and gender; 11 participants from Malawi and 20 from South Africa missing residence.

<sup>a</sup> Of records with documented HIV status. Denominators are 362 (Malawi), 957 (South Africa), and 980 (Zimbabwe).

<sup>b</sup> Among participants with HIV. Denominators are 232 (South Africa), and 366 (Zimbabwe). ART status was not available in records from Malawi.

353  
354

**Table 2. Cancer Diagnoses and Documented HIV Status of Adult Cancer Patients at Regional Cancer Treatment Centers in Malawi, South Africa, and Zimbabwe**

Diagnosis	Malawi (N=1648)						South Africa (N=1044)						Zimbabwe (N=1135)					
	HIV-		HIV+		Unknown		HIV-		HIV+		Unknown		HIV-		HIV+		Unknown	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Anal	0	0.0	1	20.0	4	80.0	0	0.0	1	100.0	0	0.0	2	15.4	10	76.9	1	7.7
Bladder	1	14.3	0	0.0	6	85.7	4	66.7	1	16.7	1	16.7	9	56.3	0	0.0	7	43.8
Bone or soft tissue	1	14.3	1	14.3	5	71.4	3	75.0	1	25.0	0	0.0	7	53.9	4	30.8	2	15.4
Breast	22	8.7	16	6.4	214	84.9	644	70.9	198	21.8	66	7.3	73	68.2	16	15.0	18	16.8
Cervical	58	12.3	35	7.4	379	80.3	1	50.0	0	0.0	1	50.0	246	50.0	229	46.5	17	3.5
CNS (primary, incl. brain)	0	0.0	2	14.3	12	85.7	1	100.0	0	0.0	0	0.0	1	50.0	0	0.0	1	50.0
Colorectal	1	3.5	3	10.3	25	86.2	24	82.8	1	3.5	4	13.8	37	72.6	8	15.7	6	11.8
Conjunctival SCC	0	0.0	0	0.0	1	100.0	--	--	--	--	--	--	--	--	--	--	--	--
Esophageal	4	5.6	1	1.4	67	93.1	1	50.0	1	50.0	0	0.0	17	56.7	9	30.0	4	13.3
Gastric	1	10.0	0	0.0	9	90.0	6	66.7	1	11.1	2	22.2	24	72.7	3	9.1	6	18.2
Head and Neck	3	6.4	2	4.3	42	89.4	2	100.0	0	0.0	0	0.0	53	48.6	40	36.7	16	14.7
Hodgkin Lymphoma	20	35.7	15	26.8	21	37.5	3	27.3	7	63.6	1	9.1	2	66.7	0	0.0	1	33.3
Kaposi Sarcoma	13	5.6	44	19.1	174	75.3	3	27.3	8	72.7	0	0.0	0	0.0	1	100.0	0	0.0
Leukemia (Acute)	--	--	--	--	--	--	0	0.0	0	0.0	2	100.0	2	100.0	0	0.0	0	0.0
Leukemia (Chronic)	2	20.0	0	0.0	8	80.0	1	50.0	1	50.0	0	0.0	--	--	--	--	--	--
Lung	0	0.0	0	0.0	14	100.0	1	100.0	0	0.0	0	0.0	13	52.0	7	28.0	5	20.0
Liver	2	15.4	0	0.0	11	84.6	6	60.0	2	20.0	2	20.0	20	57.1	6	17.1	9	25.7
Melanoma	1	20.0	1	20.0	3	60.0	1	50.0	0	0.0	1	50.0	6	60.0	1	10.0	3	30.0
Non-Hodgkin Lymphoma	38	34.2	21	18.9	52	46.9	7	50.0	7	50.0	0	0.0	0	0.0	5	100.0	0	0.0
Ovarian	0	0.0	0	0.0	10	100.0	1	50.0	1	50.0	0	0.0	9	69.2	0	0.0	4	30.8
Pancreatic or Biliary	0	0.0	1	20.0	4	80.0	2	66.7	0	0.0	1	33.3	2	33.3	1	16.7	3	50.0
Penile	0	0.0	5	22.7	17	77.3	0	0.0	1	100.0	0	0.0	1	16.7	5	83.3	0	0.0
Prostate	4	18.2	0	0.0	18	81.8	9	100.0	0	0.0	0	0.0	38	50.0	6	7.9	32	42.1
Renal	1	25.0	0	0.0	3	75.0	1	50.0	0	0.0	1	50.0	3	75.0	0	0.0	1	25.0
Vulvovaginal	1	4.4	8	34.8	14	60.9	--	--	--	--	--	--	2	20.0	8	80.0	0	0.0
Unknown	15	10.7	6	4.3	119	85.0	--	--	--	--	--	--	7	41.2	3	17.6	7	41.2
Other	3	4.6	9	13.6	54	81.8	6	60.0	1	10.0	3	30.0	40	71.4	4	7.1	12	21.4

CNS: Central nervous system; SCC: Squamous cell carcinoma

<b>Table 3. Demographic and Clinical Characteristics by HIV Status Documentation among Adult Cancer Patients at Regional Cancer Treatment Centres in Malawi, South Africa, and Zimbabwe</b>					
	Undocumented HIV Status		Documented HIV Status		p
	n	%	n	%	
<b>MALAWI</b>					
Age at Diagnosis					
<40	404	75.7	130	24.3	0.007
40-49	323	75.3	106	24.7	
50-59	247	78.7	67	21.3	
60 or older	310	84.2	58	15.8	
Gender					
Female	844	81.2	196	18.8	<0.001
Male	440	72.7	165	27.3	
Residence Proximity to Hospital					
Resides in same province as hospital	978	82.1	213	17.9	<0.001
Resides outside hospital province	301	67.5	145	32.5	
Infection-related Cancer <sup>a</sup>					
Not infection-related	614	85.9	101	14.1	<0.001
Infection-related	672	72.0	261	28.0	
<b>SOUTH AFRICA</b>					
Age at Diagnosis					
<40	12	6.9	161	93.1	0.75
40-49	20	7.8	235	92.2	
50-59	24	8.2	269	91.8	
60 or older	31	9.6	292	90.4	
Gender					
Female	79	8.2	885	91.8	0.57
Male	8	10.0	72	90.0	
Residence Proximity to Hospital					
Resides in same province as hospital	85	8.4	928	91.6	0.93
Resides outside hospital province	1	9.1	10	90.9	
Infection-related Cancer					
Not infection-related	83	8.4	911	91.6	0.44
Infection-related	4	8.0	46	92.0	
<b>ZIMBABWE</b>					
Age at Diagnosis					
<40	5	2.9	170	97.1	<0.001
40-49	14	4.9	274	95.1	
50-59	11	5.1	204	94.9	
60 or older	125	27.4	332	72.6	
Gender					
Female	84	10.1	745	89.9	<0.001
Male	71	23.2	235	76.8	
Residence Proximity to Hospital					
Resides in same province as hospital	57	14.5	336	85.5	0.55
Resides outside hospital province	98	13.2	644	86.8	
Infection-related Cancer					
Not infection-related	127	22.3	443	77.7	<0.001
Infection-related	28	5.0	537	95.0	

<sup>a</sup> We considered the following cancers to be infection-related: anal, cervical, Hodgkin and non-Hodgkin lymphomas, Kaposi Sarcoma, liver, penile, and vulvovaginal

**Table 4. Predictors of Documented HIV Status among Adult Cancer Patients at Regional Cancer Treatment Centres in Malawi, South Africa, and Zimbabwe**

<b>MALAWI</b>	<b>PR</b>	<b>95% CI</b>	<b>p</b>	<b>aPR</b>	<b>95% CI</b>	<b>p</b>
Age at Diagnosis						
<40	Ref.	--	--	Ref.	--	--
40-49	1.01	(0.81 – 1.27)	0.9	0.98	(0.79 – 1.22)	0.9
50-59	0.88	(0.68 – 1.14)	0.3	0.88	(0.69 – 1.14)	0.3
60 or older	0.65	(0.49 – 0.86)	0.002	0.66	(0.50 – 0.87)	0.003
Gender						
Female	Ref.	--	--	Ref.	--	--
Male	1.45	(1.21 – 1.73)	<0.001	1.45	(1.21 – 1.74)	<0.001
Residence Proximity to Cancer Centre						
Resides in same province as hospital	Ref.	--	--	Ref.	--	--
Resides outside hospital province	1.82	(1.52 – 2.18)	<0.001	1.68	(1.41 – 2.01)	<0.001
Infection-related Cancer						
Not infection-related	Ref.	--	--	Ref.	--	--
Infection-related	1.98	(1.61 – 2.44)	<0.001	1.92	(1.56 – 2.38)	<0.001
<b>SOUTH AFRICA</b>	<b>PR</b>	<b>95% CI</b>	<b>p</b>	<b>aPR</b>	<b>95% CI</b>	<b>p</b>
Age at Diagnosis						
<40	Ref.	--	--	Ref.	--	--
40-49	0.99	(0.94 – 1.05)	0.7	0.99	(0.94 – 1.05)	0.7
50-59	0.99	(0.94 – 1.04)	0.6	0.99	(0.94 – 1.05)	0.8
60 or older	0.97	(0.92 – 1.03)	0.3	0.97	(0.92 – 1.03)	0.4
Gender						
Female	Ref.	--	--	Ref.	--	--
Male	0.98	(0.91 – 1.06)	0.6	0.98	(0.90 – 1.07)	0.7
Residence Proximity to Hospital						
Resides in same province as hospital	Ref.	--	--	Ref.	--	--
Resides outside hospital province	0.99	(0.82 – 1.20)	0.9	0.99	(0.82 – 1.19)	0.9
Infection-related Cancer						
Not infection-related	Ref.	--	--	Ref.	--	--
Infection-related	1.00	(0.92 – 1.09)	0.9	1.01	(0.91 – 1.12)	0.8
<b>ZIMBABWE</b>	<b>PR</b>	<b>95% CI</b>	<b>p</b>	<b>aPR</b>	<b>95% CI</b>	<b>p</b>
Age at Diagnosis						
<40	Ref.	--	--	Ref.	--	--
40-49	0.98	(0.94 – 1.02)	0.3	0.96	(0.92 – 1.00)	0.04
50-59	0.98	(0.94 – 1.02)	0.3	0.96	(0.92 – 1.00)	0.06
60 or older	0.75	(0.70 – 0.80)	<0.001	0.76	(0.72 – 0.81)	<0.001
Gender						
Female	Ref.	--	--	Ref.	--	--
Male	0.85	(0.80 – 0.91)	<0.001	0.97	(0.90 – 1.04)	0.4
Residence Proximity to Hospital						
Resides in same province as hospital	Ref.	--	--	Ref.	--	--
Resides outside hospital province	1.02	(0.97 – 1.07)	0.6	0.99	(0.95 – 1.04)	0.8
Infection-related Cancer						
Not infection-related	Ref.	--	--	Ref.	--	--
Infection-related	1.22	(1.17 – 1.28)	<0.001	1.16	(1.10 – 1.22)	<0.001

aPR: adjusted prevalence ratio; CI: confidence interval; Ref: reference category; PR: prevalence ratio;  
 Multivariable models include age, gender, residence proximity to hospital, and infection-related cancer diagnosis  
<sup>a</sup> We considered the following cancers to be infection-related: anal, cervical, Hodgkin and non-Hodgkin lymphomas, Kaposi Sarcoma, liver, penile, and vulvovaginal

Figure 1. Cancer diagnoses and documented HIV status of adult cancer patients at regional cancer treatment centers in Malawi, South Africa, and Zimbabwe. Boxes indicate infection-related cancers.

